

RELATED CASE SUBMISSION			Attorney Docket: 13566-105020		Serial No.: 10/579,251	
			Applicant: Luca Gianni et al.			
			Filing Date: October 20, 2006		Group And Unit: 4173	
RELATED PENDING APPLICATIONS						
Examiner Initial		Serial No.	Filing Date	Inventor(s)	Patent No. (if applicable)	Issue Date (if applicable)
	1	09/787,461	03/02/01	Cvitkovich et al.		
	2	10/416,086	09/17/03	Takahashi et al.		
	3	10/492,320	10/21/02	Jimeno et al.		
	4	10/558,133	11/23/05	D'Incalci et al.		
	5	10/575,132	04/7/06	Donald et al.		
	6	10/579,130	05/12/06	Rowinsky et al.		
	7	10/579,160	05/11/06	Rybek		
	8	11/132,466	05/18/05	Rinehart et al.		
	9	11/261,876	10/28/05	Beijnen et al.		
	10	11/576,115	03/27/07	Allavena et al.		
	11	11/577,790	04/23/07	Gilles et al.		
	12	11/769,873	6/28/07	Cvitkovich et al.		
	13					
	14					
	15					
	16					
	17					
	18					
	19					
Examiner			Date Considered			

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5089273		1992-02-18	Rinehart et al.	
	2	5256663		1993-10-26	Rinehart et al.	
	3	5478932		1995-12-26	Rinehart et al.	
	4	5552544		1996-09-03	Fernandez et al.	
	5	6153590		2000-11-28	Andersen et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020137663		2002-09-26	Forman et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

2	20040019027	2004-01-29	Forman et al.
3	20060030571	2006-02-09	Rinehart et al.
4	20060094687	2006-04-04	Beijnen et al.
5	20070004691	2007-01-04	Donald et al.
6	20070082856	2007-04-12	Gianni et al.
7	20070128201	2007-06-07	D'Incalci et al.

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	99/58125	WO		1999-11-18	Rinehart et al.		<input type="checkbox"/>
	2	99/51238	WO		1999-10-14	Rinehart et al.		<input type="checkbox"/>
	3	05/49031	WO		2005-06-02	Rybak		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

4	02/064843	WO		2002-08-22	Haywood et al.		<input type="checkbox"/>
5	06/46080	WO		2006-05-04	Gilles et al.		<input type="checkbox"/>
6	03/039571	WO		2003-05-15	Jimeno et al.		<input type="checkbox"/>
7	06/35244	WO		2006-04-06	Allavena et al.		<input type="checkbox"/>
8	05/49029	WO		2005-06-02	Gianni et al.		<input type="checkbox"/>
9	05/49030	WO		2005-06-02	Rowinsky et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Akers, "Excipient -Drug Interactions in Parenteral Formulations," Journal of Pharmaceutical Sciences, 91(11), pp. 2283-2300, Nov. 2002	<input type="checkbox"/>
	2	Barrera, H. et al., "Interaction of ET-743 and standard cytotoxic agents against a panel of human tumor cell lines," Proceedings of the American Association for Cancer Research, Volume 40, page 591, Abstract No. 3896, March 1999	<input type="checkbox"/>
	3	Biroccio et al., "Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells," Molecular Pharmacology, 63:632-638 (2003)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

4	Blay et al., "Combination of Trabectedin and Doxorubicin for the Treatment of Patients with Soft Tissue Sarcoma: Safety and Efficacy Analysis," 43rd annual ASCO meeting, June 1-5, 2007	<input type="checkbox"/>
5	BONFANTI, et al., Effect of Ecteinascidin-743 on the Interaction Between DNA Binding Proteins and DNA. Anticancer Drug Des. 14, 179-86, 1999	<input type="checkbox"/>
6	Bowman, A. et al., "Phase I clinical and pharmacokinetic (PK) study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days," Annals Oncology, Abstract 452, 1998	<input type="checkbox"/>
7	Brandon et al., "In-vitro Cytotoxicity of ET-743 (Trabectedin, Yondelis), a Marine Anti-cancer Drug, in the Hep G2 Cell Line: Influence of Cytochrome P450 and Phase II Inhibition, and Cytochrome P450 Induction, Anti-cancer Drugs, 16:935-943 (2005)	<input type="checkbox"/>
8	European Agency for the Evaluation of Medicinal Products, "Committee for Proprietary Medicinal Products Summary of Opinion for Yondelis", November 20, 2003	<input type="checkbox"/>
9	Corey et al., "Enantioselective Total Synthesis of Ecteinascidin 743", J. Am. Chem. Soc., 118, 9202-9203, 1996	<input type="checkbox"/>
10	Cvitkovic, E. et al., "Final results of a phase I study of ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients (pts)," 1999 ASCO Annual Meeting Proceedings, Abstract No. 690, May 15-18, 1999	<input type="checkbox"/>
11	Cvitkovic, E. et al., "Ecteinascidin-743 (ET-743) 24 hour continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients," Annals Oncology, Abstract 456, 1998	<input type="checkbox"/>
12	Hendriks, H.R. et al., "High antitumor activity of ET743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer," Annals of Oncology, vol. 10, pages 1233-1240, 1999	<input type="checkbox"/>
13	Hidalgo, M., et al., "A phase I and pharmacokinetic (PK) study of ET-743, a novel minor groove binder of marine origin administered on a daily x 5 schedule," 23rd European Society for Medical Oncology Congress, Abstract No. 613P, November 6-10, 1998	<input type="checkbox"/>
14	Delaloge, S. et al., "Ecteinascidin-743: A Marine-Derived Compound in Advanced Pretreated Sarcoma Patients- Preliminary Evidence of Activity", J. of Clinical Oncology, vol. 19, no. 5, pp. 1248-1255, 2001	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

15	DeVita et al., "Combination Versus Single Agent Chemotherapy: A Review of the Basis for Selection of Drug Treatment of Cancer", Cancer, vol. 35, pp. 98-110, 1975	<input type="checkbox"/>
16	D'Incalci et al., "The Combination of ET-743 and Cisplatin (DDP): From a Molecular Pharmacology Study to a Phase I Clinical Trial," from the AACR Annual Meeting of April 6-10, 2002, Abstract 404	<input type="checkbox"/>
17	D'Incalci et al., "In human tumor xenografts the resistance to ET-743 or to cisplatin can be overcome by giving the two drugs in combination," European Journal of Cancer, 38, Suppl. 7, 34 (November 2002)	<input type="checkbox"/>
18	D'Incalci et al., "Preclinical and Clinical Results with the Natural Marine Product ET-743," Expert Opin. Investig. Drugs, 12(11):1843-1853 (2003).	<input type="checkbox"/>
19	D'Incalci et al., "The combination of yondelis and cisplatin is synergistic against human tumor xenografts," European Journal of Cancer 39: 1920-1926 (2003)	<input type="checkbox"/>
20	Donald et al., "Complete Protection By High-Dose Dexamethasone Against The Hepatotoxicity of the Novel Antitumor Drug Yondelis (ET-743) in The Rat," Cancer Research, Vol. 63, p. 5902-5908, September 2003	<input type="checkbox"/>
21	Donald et al., "Dietary Agent Indole-3-Carbinol Protects Female Rats Against the Hepatotoxicity of the Antitumor Drug ET-743 (trabectedin) Without Compromising Efficacy in a Rat Mammary Carcinoma" International Journal Of Cancer, Vol. 111, No.6, p. 961-967, 2004	<input type="checkbox"/>
22	"Doxil (doxorubicin Hcl Liposome Injection) Product Information", October 10, 2004, pages 1-16, XP002389462, web.archive.org/web/20041009180	<input type="checkbox"/>
23	Drugs Fut., "Ecteinascidin-743" vol. 22, no. 11, page 1279, 1997	<input type="checkbox"/>
24	Eckhardt et al., "In vitro Studies of a Novel Marine Cytotoxic, Ecteinascidin (ET-743)," New Drugs and Pharmacology, Annals of Oncology, 7 (Suppl. 5), 131, Abstract 632P (1996)	<input type="checkbox"/>
25	Endo et al., "Total Synthesis of Ecteinascidin 743", J. Am. Chem. Soc., 124, 6552-6554, 2002	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

26	Erba et al., "Synergistic cytotoxic effect of ET-743 and cisplatin," Clinical Cancer Research, Vol. 6, Abstract 209 (November 2000)	<input type="checkbox"/>
27	Erba et al., "Combination of yondelis (ET-743) and oxaliplatin in experimental ovarian cancer," from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics of Nov. 17-21, 2003, Abstract C247	<input type="checkbox"/>
28	Erba et al., "ET-743 and Cisplatin (DDP) Show in Vitro and in Vivo Synergy Against Human Sarcoma and Ovarian Carcinoma Cell Lines," from the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics of October 29 – November 2, 2001, Abstract 406	<input type="checkbox"/>
29	FDA approved label for Pharmacia and Upjohn's Doxorubicin Hydrochloride for Injection (May 8, 2003).	<input type="checkbox"/>
30	Faircloth et al., "In Vivo Combinations of Chemotherapeutic Agents with Ecteinascidin 743 (ET743) Against Solid Tumors," from the Proceedings AACR-NCI-EORTC of November 2001, Abstract 387.	<input type="checkbox"/>
31	Faircloth et al., "Dexamethasone Potentiates the Activity of Ecteinascidin 743 in Preclinical Melanoma and Osteosarcoma Models," Abstract and Presentation 379 (2002).	<input type="checkbox"/>
32	Fayette et al., "ET-743: a Novel Agent with Activity in Soft-Tissue Sarcomas," Current Opinion in Oncology, 18:347-353 (2006).	<input type="checkbox"/>
33	Fourouzesh, B. et al., "Phase I and pharmacokinetic study of the marine-derived DNA minor groove binder ET-743 on a weekly x3 every-4-week schedule in patients with advanced solid malignancies," Proceedings of the 2001 AACR-NCI-EOTRC International Conference, Abstract No. 209, October 29-November 2, 2001	<input type="checkbox"/>
34	Fourouzesh, B. et al., "Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer," Proc Am Soc Clin Oncol, vol 20, 2001 ASCO Annual Meeting Proceedings, Abstract No. 373, 2001	<input type="checkbox"/>
35	Forouzesh, B., et al., "Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer," European Journal of Cancer, ECCO 11, volume 37, supplement 6, Abstract No. 106, October 21-25, 2001	<input type="checkbox"/>
36	Fukuyama et al., "Total Synthesis of Saframycin A," J. Am. Chem. Soc., 112, 3712-3713, 1990	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

37	Fukuyama et al., "Stereocontrolled Total Synthesis of Saframycin B," J. Am. Chem. Soc., 104, 4957-4958, 1982	<input type="checkbox"/>
38	Garcia Gravalos, M.D., et al., "In vitro schedule-dependent cytotoxicity by ecteinascidin 743 (ET-743) against human tumor cells," 23rd European Society for Medical Oncology Congress, Abstract No. 652, November 6-10, 1998	<input type="checkbox"/>
39	Ghielmini, M. et al., "Schedule-dependent myelotoxicity induced in vitro by the new marine derived minor groove interacting agent ecteinascidin 743," ECCO, vol. 9, Abstract No. 807, September 17, 1997	<input type="checkbox"/>
40	Ghielmini, M. et al., "In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)," Annals of Oncology, vol. 9, pages 989-993, 1998	<input type="checkbox"/>
41	Hillebrand, M.J.X. et al., "Pharmacokinetics of ecteinascidin-743 (ET-743) in three phase I studies," Annals Oncology, Abstract No. 455, 1998	<input type="checkbox"/>
42	Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, page 36, 1975	<input type="checkbox"/>
43	Goodman & Gilman's The Pharmaceutical Basis of Therapeutics (9th edition), page 930, 1996	<input type="checkbox"/>
44	Goodman & Gilman's The Pharmaceutical Basis of Therapeutics (9th edition), pages 1230. 1232, 1996	<input type="checkbox"/>
45	Grever et al., "The National Cancer Institute: Cancer Drug Discovery and Development Program", Seminars in Oncology, vol. 19, no. 6, 622-638, December 1992	<input type="checkbox"/>
46	Grosso et al., "Steroid Premedication Markedly Reduces Liver and Bone Marrow Toxicity of Trabectedin in Advanced Sarcoma," European Journal of Cancer 42:10, 1484-1490 (2006)	<input type="checkbox"/>
47	Gurtler, J.S. et al., "Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens," Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, vol. 23, no. 16S, part 1 of 2 (June 1 Supplement), Abstract No. 625, 2005	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10579251
	Filing Date		2006-10-20
	First Named Inventor	Luca Gianni et al.	
	Art Unit	4173	
	Examiner Name	Jonathan S. Lau	
	Attorney Docket Number	13566.105020	

48	Merck Manual on-line edition version, "Types: Overview of Cancer," 4 pages, downloaded from internet website << http://www.merck.com/mmhe >>, February 2003	<input type="checkbox"/>
49		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

1	Holmes, "Paclitaxel Combination Therapy in the treatment of Metast Breast Cancer: A Review," Seminars in Oncology, vol. 23, pp. 46-56, 1996	<input type="checkbox"/>
2	Hornicek et al., "Effect of Ecteinascidin-743 and Plasminogen related Protein B on a Human Chondrosarcoma Xenograft Tumor in Mice," Clinical Cancer Research, Vol. 7 Supplement P3734S-3734S, Abstract 398 (November 2001)	<input type="checkbox"/>
3	Ishikawa et al., "Tumor Selective Delivery of 5-Fluorouracil by Capecitabine," Biochemical Pharmacology, vol. 55, pp. 1091-1097, 1998	<input type="checkbox"/>
4	Izbicka, E. et al., "In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC- 648766) against human tumors explanted from patients," Annals of Oncology, vol. 9, pages 981-987, 1998	<input type="checkbox"/>
5	Jimeno, J.M. et al., "Enhancing the preclinical in vivo antitumor activity of ecteinascidin 743, a marine natural product currently in phase II clinical trials," Proceedings of the 1999 AACR-NCI-EORTC International Conference, Clinical Cancer Research, Volume 5, Abstract No. 306, November 1999	<input type="checkbox"/>
6	Jimeno, J. et al., "Phase I and pharmacokinetic (PK) study of Et-743, a novel minor groove binder of marine origin on a daily [times] 5 schedule," 1998 ASCO Annual Meeting Proceedings, Abstract No. 737, 1998	<input type="checkbox"/>
7	Jimeno, Jose et al., "Adding Pharmacogenomics to the Development of New Marine-Derived Anticancer Agents," Journal of Translational Medicine, volume 4, issue 3, January 9, 2006, downloaded from the internet website: << http://www.translational-medicine.com/content/4/1/3 >>	<input type="checkbox"/>
8	JIN, et al., Ecteinascidin-743, A Transcription-Targeted Chemotherapeutic that Inhibits MDR 1 Activation. Proc. Natl. Acad. Sci. USA, 97, 6775-9, 2000	<input type="checkbox"/>
9	Kanzaki et al., "Activity of Ecteinascidin 743 and Synergism with Doxorubicin and Vincristine in P-Glycoprotein/MDR1 Over-Expression Cell Lines," from the Proceedings of the AACR, Vol. 42, Abstract 4354 (March 2001)	<input type="checkbox"/>
10	Kanzaki et al., "Microsatellite Instability (MSI) Induced by Ecteinascidin743 and Protection with Aspirin," from the 93rd Annual Meeting of the American Association for Cancer Research, Abstract 5382 (April 6-10, 2002)	<input type="checkbox"/>
11	Kesteren et al., "Yondelis® (Trabectedin, ET-743): The Development of an Anticancer Agent of Marine Origin" Anti-Cancer Drugs, Vol. 14, No. 7, p.487-502, 2003	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

12	Leonetti et al., "Antitumoral Effect of the G-quadruplex Interactive Compound RHPS4 on Human Melanoma Cells Possessing Relatively Long Telomeres," from the Proceedings of the AACR, Volume 45, March 2004	<input type="checkbox"/>
13	Maier et al., "In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the antiendoglin antibody TEC-11," Anti-Cancer Drugs, vol. 8, pp. 238-244, 1997	<input type="checkbox"/>
14	Magro et al., "The Role of PARP and PARP Inhibitors in Yondelis (Trabectedin) Mediated Cytotoxicity," Abstract and Presentation from the AACR Annual Meeting, April 17, 2007	<input type="checkbox"/>
15	MARTINEZ, et al., Phthalascidin, A Synthetic Antitumor Agent with Potency and Mode of Action Comparable to Ecteinascidin 743. Proc. Natl. Acad. Sci. USA 96; 3496-501, 1999	<input type="checkbox"/>
16	MARTINEZ, E. J. et al., A New, More Efficient, and Effective Process for the Synthesis of a Key Pentacyclic Intermediate for Production of Ecteinascidin and Phthalascidin Antitumor Agents. Org. Lett. 2, 993-6, 2000	<input type="checkbox"/>
17	McLeod, "Clinically relevant drug-drug interactions in oncology," Br. J. Clin. Pharmacol., 45:539-544 (1998)	<input type="checkbox"/>
18	McMeekin, D.S. et al., "Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma," Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Vol. 23, No. 16S, Part I of II (June 1 Supplement), Abstract No. 5011, May 13-17, 2005	<input type="checkbox"/>
19	Meco et al., "Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies," Cancer Chemother. Pharmacol. 52: 131-138 (2003)	<input type="checkbox"/>
20	Meco et al., "The combination of ET-743 and Irinotecan is active in preclinical models in rhabdomyosarcoma," presented at the 16th EORTC-NCI-AARC Symposium on Molecular Targets and Cancer Therapeutics held in Geneva on September 28 - October 1, 2004	<input type="checkbox"/>
21	Takahashi et al., "Sequence-dependent Synergistic Cytotoxicity of Ecteinascidin-743 and Paclitaxel in Human Breast Cancer Cell Lines in Vitro and in Vivo," Cancer Research, 62: 6909-6915 (Dec. 1, 2002)	<input type="checkbox"/>
22	Michaelson, M.D. et al., "Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC)," Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Vol. 23, No. 16S, Part I of II (June 1 Supplement), Abstract No. 4517, May 13- 17, 2005	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

23	MINUZZO, M. et al., "Interference of Transcriptional Activation by the Antineoplastic Drug Ecteinascidin.743." Proc. Natl. Acad. Sci. USA 97, 6780-4, 2000	<input type="checkbox"/>
24	Moore et al., "Sequencing evaluation of ET-743 combinations with standard chemotherapy agents against a panel of human tumor cell lines," Clinical Cancer Research, Vol. 6, Abstract 504 (November 2000)	<input type="checkbox"/>
25	Morioka et al., "Antiangiogenesis Treatment Combined with Chemotherapy Produces Chondrosarcoma Necrosis," Clinical Cancer Research, Vol. 9, 1211-1217, March 2003	<input type="checkbox"/>
26	Pharma Mar Press Release, "PharmaMar Differs with CPMP Opinion", Pharma Mar Grupo Zeltia, << http://www.pharmamar.com/en/press/news_release.cfm >>, July 24, 2003	<input type="checkbox"/>
27	Pharma Mar Press Release, "PharmaMar Receives EMEA Appeal Decision on Yondelis in Soft Tissue Sarcoma", Pharma Mar Grupo Zeltia, << http://www.pharmamar.com/en/press/news_release.cfm >>, November 20, 2003	<input type="checkbox"/>
28	Pharma Mar Press Release, "YONDELIS(r) STS-201 Efficacy and Safety Data Presented at ASCO 2007" Pharma Mar Grupo Zeltia, << http://www.pharmamar.com/en/press >>, June 5, 2007	<input type="checkbox"/>
29	Pharma Mar Press Release, "The European Commission Authorizes YONDELIS(r) Commercialization for Soft Tissue Sarcoma" Pharma Mar Grupo Zeltia, << http://www.pharmamar.com/en/press >>, September 20, 2007	<input type="checkbox"/>
30	POMMIER, et al., "DNA Sequence- And Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia Turbinata." Biochemistry 35, 13303-9, 1996	<input type="checkbox"/>
31	RINEHART, K.L., "Antitumor Compounds from Tunicates." Moo. Res. Rev. 20, 1-27, 2000	<input type="checkbox"/>
32	Riccardi et al., "Preclinical Activity and Biodistribution of Ecteinascidin 743 (ET-743) and Doxorubicin (DOX) Combinations in Human Rhabdomyosarcoma," from the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics of October 29 – November 2, 2001, Abstract 405	<input type="checkbox"/>
33	Riccardi et al., "Effective Combinations of ET-743 and Doxorubicin for Tumor Growth Inhibitions Against Murine and Human Sarcomas in Athymic Mice," from the Proceedings of the AACR, Vol. 42, Abstract 1132 (March 2001)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

34	Riccardi et al., "Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft," Anti-Cancer Drugs, 16:811-815 (2005)	<input type="checkbox"/>
35	Riofrio, M. et al., "Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study progressive report," 23rd European Society for Medical Oncology Congress, Abstract 639P, November 6-10, 1998	<input type="checkbox"/>
36	Robert et al., "Pharmacokinetics of Doxorubicin in Sarcoma Patients," Eur. J. Clin. Pharmacol., vol. 31, pp. 695-699, 1987	<input type="checkbox"/>
37	Ryan, DP et al., "Phase I and Pharmacokinetic Study of Ecteinascidin-743 Administered as a 72 hours Continuous Intravenous Infusion in Patients with Solid Malignancies", Clinical Cancer Research, Vol. 7, pp. 231-242, 2001	<input type="checkbox"/>
38	Saito et al., "Synthesis of Saframycins- 3," J. Org. Chem., 54, 5391, 1989	<input type="checkbox"/>
39	Sato et al., "Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)," Japanese Journal of Clinical Oncology, Vo. 33, no. 8, pp. 371-376, August 2003	<input type="checkbox"/>
40	Scotlandi et al., "Effectiveness of Ecteinascidin-743 against Drug-sensitive and -resistant Bone Tumor Cells," Clinical Cancer Research, 8:3893-3903 (December 2002)	<input type="checkbox"/>
41	Sessa et al., "Trabectedin for Women with Ovarian Carcinoma After Treatment with Platinum and Taxane Fails," Journal of Clinical Oncology," vol. 23,no. 9, pp. 1867-1874, March 20, 2005	<input type="checkbox"/>
42	Smyth, "Rationale for Drug Combinations," European Journal of Cancer, 39, 1816-1817 (2003)	<input type="checkbox"/>
43	Taamma, A. et al., "Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): clinical and pharmacokinetic phase I study in solid tumor patients (PTS). Preliminary Results" 1998 ASCO Annual Meeting Proceedings, Abstract No. 890, 1998	<input type="checkbox"/>
44	Taamma, A. et al., "Phase I clinical study of ecteinascidin-743 (ET-743) as a 24 hours continuous intravenous infusion (CI) in patients (pts) with solid tumors (st): A progress report," ECCO, vol. 9, Abstract No. 1119, September 18, 1997	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

45	Taamma et al., "Phase I Clinical Study of ecteinascidin-743 (ET-743)," Eur. J. Cancer, 33 Suppl. 8, S247-S248, 1997, Abstract	<input type="checkbox"/>
46	Taamma et al., "Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24 hours Continuous Infusion in Patients with Solid Tumors", J. of Clinical Oncology, vol. 19, no. 5, pp. 1256-1265, 2001	<input type="checkbox"/>
47	Tabor et al., "Anti oxidation Potential of Indole Compounds-Structure Activity Studies," Biological Reactive Intermediates IV, p. 833-836, 1990	<input type="checkbox"/>
48	TAKEBAYASHI, et al., "Poisoning of Human DNA Topoisomerase I by Ecteinascidin 743, An Anticancer Drug That Selectively Alkylates DNA in the Minor Groove." Proc. Natl. Acad. Sci. USA 96, 7196-201 1999	<input type="checkbox"/>
49	Takahashi et al., "Ecteinascidin 743 (ET-743) and doxorubicin produce synergistic cytotoxic effects in soft tissue sarcoma lines HT-1080 and HS-18," Clinical Cancer Research, Vol. 6, Abstract 208 (November 2000)	<input type="checkbox"/>
50		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

1	Erichman, C., "18: Pharmacology of Anticancer Drugs,"The Basic Science of Oncology, 2nd edition, Tannock et al., editors, McGraw-Hill, New York, pages 317-337, 1992	<input type="checkbox"/>
2	Twelves, C.J. et al., "Phase I clinical and pharmacokinetic (PK) study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days," 1998 ASCO Annual Meeting Proceedings, Abstract No. 889, 1998	<input type="checkbox"/>
3	Twelves, C.J. et al., "Phase I and pharmacokinetic study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days," ECCO, vol. 9, Abstract No. 1107, September 18, 1997	<input type="checkbox"/>
4	Twelves et al., "A Phase I and Pharmacokinetic (PK) study of Et-743 evaluating a 3 hours (h) intravenous (iv) infusion (I) in patients (pts) with solid tumors," Clinical Cancer Research, Abstract #307, 5 (11, suppl. 3790S-3791S) 1999	<input type="checkbox"/>
5	Valoti, G., et al., "Ecteinascidin-743 (ET-743), a marine natural compound, shows antitumor activity against human ovarian carcinoma xenografts," Novel Therapeutics and Pharmacology, pageS39, Abstract PP179, 1998	<input type="checkbox"/>
6	Valoti, "Ecteinascidin-743, a New Marine Natural Product with Potent Antitumor Activity on Human Ovarian Carcinoma Xenografts," Clin. Cancer Res., vol. 4, pages 1977-83, August 1998	<input type="checkbox"/>
7	Villalona-Calero, M. et al., "A phase I and pharmacokinetic study of ET-743, a novel DNA minor groove binder of marine origin, administered as a 1-hour infusion daily x 5 days," Annals Oncology, Abstract 453, 1998	<input type="checkbox"/>
8	Villalona-Calero, M. et al., "Final results of a Phase I and pharmacokinetic (PK) study of the marine minor groove binder ET-743 on a daily x 5 schedule," 1999 ASCO Annual Meeting Proceedings, Abstract No. 691, 1999	<input type="checkbox"/>
9	Wiesenthal, "Is one 'sensitive' drug better than another?" downloaded from internet website << http://weisenthal.org/feedback.html >>, Feb. 4, 2002	<input type="checkbox"/>
10	Wright et al., "Antitumor Tetrahydroisoquinoline Alkaloids from the Colonial Ascidian Ecteinascidia Turbinata", J. Org. Chem., vol. 55, pp. 4508-4512, 1990	<input type="checkbox"/>
11	ZEWAIL-FOOTE, et al., "Ecteinascidin 743: A Minor Groove Alkylator that Bends DNA Toward the Major Groove," J. Med. Chem. 42, 2493-7, July 15, 1999	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579251
Filing Date	2006-10-20
First Named Inventor	Luca Gianni et al.
Art Unit	4173
Examiner Name	Jonathan S. Lau
Attorney Docket Number	13566.105020

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.